Cargando…
Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS
BACKGROUND: In PARADIGMS, a double-blind phase III trial in 215 paediatric patients with multiple sclerosis (MS) (10 to <18 years), fingolimod administered for up to 2 years significantly reduced the annualised relapse rate (ARR) and rate of new/newly enlarged T2 (n/neT2) lesions compared with in...
Autores principales: | Deiva, Kumaran, Huppke, Peter, Banwell, Brenda, Chitnis, Tanuja, Gärtner, Jutta, Krupp, Lauren, Waubant, Emmanuelle, Stites, Tracy, Pearce, Gregory Lewis, Merschhemke, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952840/ https://www.ncbi.nlm.nih.gov/pubmed/31467033 http://dx.doi.org/10.1136/jnnp-2019-321124 |
Ejemplares similares
-
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study
por: Arnold, Douglas L, et al.
Publicado: (2020) -
Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study
por: Krupp, Lauren, et al.
Publicado: (2022) -
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016) -
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021) -
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
por: Meyer-Arndt, Lil, et al.
Publicado: (2022)